Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Russell Enedy

Physician Assistant Johnstown, PA Physician Assistant

NPI 1770819096 CMS profile 10568194

1111 Franklin St, Suite 410, Johnstown, PA 15905

Open in the dashboard

General payments

$5,899

356 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Russell Enedy of Johnstown, PA is reported in the CMS Open Payments database as having received $5,899 across 356 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,342 82
2024 General $1,143 68
2023 General $1,192 72
2022 General $1,418 75
2021 General $804 59

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Russell Enedy
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Russell Enedy were reported at $1,342. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Russell Enedy Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $804 $132 $37–$438 $132
2022 $1,418 $155 $48–$522 $149
2023 $1,192 $167 $52–$557 $160
2024 $1,143 $178 $55–$600 $164
2025 $1,342 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Astellas Pharma US Inc $870 58 payments
  2. Sumitomo Pharma America, Inc. $869 75 payments
  3. Pfizer Inc. $584 35 payments
  4. Janssen Biotech, Inc. $577 33 payments
  5. Tolmar, Inc. $434 23 payments
  6. AbbVie, Inc. $433 21 payments
  7. Merck Sharp & Dohme Corporation $274 14 payments
  8. Myovant Sciences Inc. $269 20 payments
  9. TOLMAR Pharmaceuticals, Inc. $239 12 payments
  10. Ferring Pharmaceuticals Inc. $219 13 payments
  11. Other $1,132 52 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,824 351 payments
  2. Education $75 5 payments
Products named General payments · program years 2021–2025
  1. XTANDI $1,049 64 payments
  2. ORGOVYX Hormone Therapy $595 51 payments
  3. ORGOVYX Oncology $543 32 payments
  4. ERLEADA $540 31 payments
  5. GEMTESA $407 26 payments
  6. MYRBETRIQ $391 31 payments
  7. ELIGARD $386 21 payments
  8. LUPRON DEPOT $281 14 payments
  9. KEYTRUDA $274 14 payments
  10. ORGOVYX Prostate Cancer $233 23 payments
  11. Other $2,822 143 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

362

Median for Physician Assistant: 241

Drug cost

$9,370

Median for Physician Assistant: $4,110

Branded share of claims

14.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tamsulosin Hcl Generic 138 $2,432
Dutasteride Generic 25 $1,594
Estradiol Generic 14 $1,523
Potassium Citrate Er Potassium Citrate Brand 18 $1,314
Solifenacin Succinate Generic 27 $1,146
Finasteride Generic 45 $706
Fluconazole Generic 11 $211
Cephalexin Generic 17 $120
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 18 $106
Oxybutynin Chloride Generic 13 $94

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$114,211

Medicare's payments for the services billed

Medicare patients

148

Average age 73

Services billed

665

50 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Chronic kidney disease 51%
Ischemic heart disease 44%
Diabetes 39%
Depression 34%
Heart failure 31%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ORGOVYX
  • Sumitomo Pharma America, Inc. $197
  • PFIZER INC. $21
$218 — —
XTANDI
  • Astellas Pharma US Inc $133
  • PFIZER INC. $21
$154 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $105
$105 — —
ELIGARD
  • TOLMAR, INC. $98
$98 — —
ERLEADA
  • Janssen Biotech, Inc. $88
$88 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

356 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record